Last reviewed · How we verify
Marcaine 0.25 % Injectable Solution
Marcaine 0.25 % Injectable Solution is a Local anesthetic Small molecule drug developed by Connecticut Children's Medical Center. It is currently FDA-approved for Local anesthesia for infiltration, nerve block, epidural, and spinal anesthesia, Pediatric anesthesia and pain management. Also known as: bupivacaine 0.25% injectable solution.
Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.
Marcaine 0.25% Injectable Solution is a local anesthetic used in various medical procedures, including anesthesia, postoperative pain management, and treatment of conditions such as cervical radiculopathy and migraine headache. It is a bupivacaine solution, which is an oligosaccharide modality.
At a glance
| Generic name | Marcaine 0.25 % Injectable Solution |
|---|---|
| Also known as | bupivacaine 0.25% injectable solution |
| Sponsor | Connecticut Children's Medical Center |
| Drug class | Local anesthetic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Bupivacaine reversibly binds to and blocks voltage-gated sodium channels on the inner surface of nerve cell membranes, preventing depolarization and action potential propagation. This results in local anesthesia and loss of sensation in the infiltrated tissue. The drug has a relatively long duration of action compared to other local anesthetics due to its high lipophilicity and protein binding.
Approved indications
- Local anesthesia for infiltration, nerve block, epidural, and spinal anesthesia
- Pediatric anesthesia and pain management
Common side effects
- Systemic toxicity (CNS effects: tremor, seizures)
- Cardiovascular effects (hypotension, bradycardia, arrhythmias)
- Local reactions (pain at injection site)
- Allergic reactions
Key clinical trials
- The Efficacy and Safety of Liposomal Bupivacaine for Transversus Abdominis Plane Block in Relieving Postoperative Pain After Laparoscopic Surgery (NA)
- The Efficacy and Safety of Liposomal Bupivacaine for Transversus Abdominis Plane Block in Relieving Postoperative Pain After Laparoscopic Surgery in Gynecologic Oncology (NA)
- Cervicothoracic Sympathetic Block Evaluation for Post COVID Condition (PHASE4)
- Efficacy of Nerve Blocks for Episodic Migraine (PHASE2)
- The Efficacy and Safety of Liposomal Bupivacaine for Rhomboid Intercostal Nerve Block in Relieving Postoperative Pain After Video-assisted Thoracoscopic Surgery (NA)
- Comparison Of Clinical Outcomes of Intraperitoneal Bupivacaine Instillation Versus Placebo as Preemptive Analgesia in Patients Undergoing Open Appendectomy (PHASE1)
- Comparison of Erector Spinae Plane Block and Caudal Block in Pediatric Patients Aged 1 to 8 Years Undergoing Lower Abdominal Surgery (NA)
- Efficacy of Transversus Abdominis Plane Block in Alleviating Acute Appendicitis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Marcaine 0.25 % Injectable Solution CI brief — competitive landscape report
- Marcaine 0.25 % Injectable Solution updates RSS · CI watch RSS
- Connecticut Children's Medical Center portfolio CI
Frequently asked questions about Marcaine 0.25 % Injectable Solution
What is Marcaine 0.25 % Injectable Solution?
How does Marcaine 0.25 % Injectable Solution work?
What is Marcaine 0.25 % Injectable Solution used for?
Who makes Marcaine 0.25 % Injectable Solution?
Is Marcaine 0.25 % Injectable Solution also known as anything else?
What drug class is Marcaine 0.25 % Injectable Solution in?
What development phase is Marcaine 0.25 % Injectable Solution in?
What are the side effects of Marcaine 0.25 % Injectable Solution?
What does Marcaine 0.25 % Injectable Solution target?
Related
- Drug class: All Local anesthetic drugs
- Target: All drugs targeting Voltage-gated sodium channels
- Manufacturer: Connecticut Children's Medical Center — full pipeline
- Therapeutic area: All drugs in Anesthesia
- Indication: Drugs for Local anesthesia for infiltration, nerve block, epidural, and spinal anesthesia
- Indication: Drugs for Pediatric anesthesia and pain management
- Also known as: bupivacaine 0.25% injectable solution
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing